We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mrs
Marcia
de Souza Lima
+41 (0) 79 531 5257
registry@belkin-vision.com
More information about this study, what is involved and how to take part can be found on the study website.
Glaucoma and ocular hypertension
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This study is designed to evaluate the performance and safety of the Eagle® device when used within the intended use covered by the CE marking and following the Standard of Care. The Eagle device is a laser device for direct selective laser trabeculoplasty (DSLT) for the treatment of glaucoma. The laser treatment with the Eagle device is performed without the need to use a lens that touches the eye as in the traditional laser treatment. An image processing algorithm automatically localises the target area, which the operator or eye care professional (ECP) readjusts if necessary. Once the operator has confirmed the target area, an eye-tracking system enables the eye movement to be tracked so that the laser pulses are delivered precisely to the target area.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
Records of participants with any of the following conditions at the date of the treatment with the Eagle device, will not be included in the data collection: 1. Participants who are unable to fixate their head and/or eyes, such as participants suffering from nystagmus, tremors or similar conditions.2. Participants with congenital glaucoma or active anterior segment inflammations.3. Participants with any condition that obscures the limbus, such as melanosis affecting the limbus, severe arcus senilis affecting the limbus, pterygium affecting the limbus or any other such conditions.4. Participants with any condition that causes poor visualization of the limbus that prevents the Eagle device’s treatment target identification.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mrs
Marcia
de Souza Lima
+41 (0) 79 531 5257
registry@belkin-vision.com
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by BELKIN Vision Ltd. and funded by BELKIN Vision Ltd..
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 60903
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
